Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Peter Schmid(Queen Mary University of London), Jacinta Abraham(National Health Service), Stephen Chan(Nottingham University Hospitals NHS Trust), Duncan Wheatley(Royal Cornwall Hospital Trust), Adrian Murray Brunt(University Hospitals of North Midlands NHS Trust), Gia Nemsadze, Richard D. Baird(Cancer Research UK Cambridge Center), Yeon Hee Park(Samsung Medical Center), Peter Hall(Edinburgh Cancer Research), Timothy Perren(Leeds Teaching Hospitals NHS Trust), Robert C. Stein(University College London Hospitals NHS Foundation Trust), László Mangel(University of Pecs), Jean-­Marc Ferrero(Centre Antoine Lacassagne), Melissa Phillips(Barts Health NHS Trust), John Conibear(Barts Health NHS Trust), Javier Cortés(Instituto Cajal), Andrew Foxley(AstraZeneca (United Kingdom)), Elza C. de Bruin(AstraZeneca (United Kingdom)), Robert McEwen(AstraZeneca (United Kingdom)), Daniel Stetson(AstraZeneca (United States)), Brian Dougherty(AstraZeneca (United States)), Shah‐Jalal Sarker(Queen Mary University of London), Aaron Prendergast(Queen Mary University of London), Max McLaughlin-Callan(Queen Mary University of London), Matthew Burgess(Queen Mary University of London), Cheryl Lawrence(Queen Mary University of London), Hayley Cartwright(Queen Mary University of London), Kelly Mousa(Queen Mary University of London), Nicholas C. Turner(Institute of Cancer Research)
Journal of Clinical Oncology
December 16, 2019
Cited by 388Open Access
Full Text

Abstract

PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m 2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/ AKT1/ PTEN alterations, tumor response, and safety. RESULTS Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/ AKT1/ PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade ≥ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/ AKT1/ PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.


Related Papers

No related papers found

Powered by citation graph analysis